The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials

Kennedy Institute of Ethics Journal 24 (2):121-139 (2014)

Abstract

Should first-in-human trials be designed to maximize the prospect of therapeutic benefit for volunteers, prioritize avoidance of unintended harms, or aim for some happy medium between the two? Perennial controversies surrounding initiation and design of early-phase trials hinge on how this question is resolved. In this paper, we build on the premise that the task of early-phase testing is to optimize various components of a potential therapy so that later, confirmatory trials have the maximal probability of informing drug development and clinical care. We then explore three strategies that investigators might use to manage trial risks while optimizing a therapy, using cell therapy for Amyotrophic Lateral Sclerosis (ALS) as an example. We argue that an iterative application of maximin strategies over successive cohorts and trials, which we call the “risk-escalation model,” establishes a moral principle that should guide decision-making in early-phase trials.

Download options

PhilArchive



    Upload a copy of this work     Papers currently archived: 72,805

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Analytics

Added to PP
2014-07-02

Downloads
31 (#373,294)

6 months
1 (#386,499)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Spencer Hey
Harvard University

Citations of this work

Can Risks Be Offset by the Prospect of Benefit in Trial Design?Hannah Grankvist - 2015 - American Journal of Bioethics Neuroscience 6 (1):61-62.

Add more citations

Similar books and articles

Prudent Precaution in Clinical Trials of Nanomedicines.Gary E. Marchant & Rachel A. Lindor - 2012 - Journal of Law, Medicine and Ethics 40 (4):831-840.
Two Concepts of Therapeutic Optimism.L. A. Jansen - 2011 - Journal of Medical Ethics 37 (9):563-566.